

## Wasazra Pharma to expand its biz in India

23 August 2018 | News | By Sonali Wankhade

**3rd Eye Advisory Ltd. is the strategic consultant for its business growth and marketing.**



Wasazra is one of the emerging pharmaceutical companies in India, whose goal is to ensure that no patient is denied access to high quality & affordable medicines. The company has spread across Uttar Pradesh with presence in more than 50 territories.

This public limited company is led by Mr. Syed Mohammad Fauzan Akhtar, a young entrepreneur spreading his wings in pharma industry by giving affordable and result oriented medicines.

Wasazra started its business in June 2017 and has grown multifold in a span of one year and now plans to expand its business operations throughout India.

3rd Eye Advisory Ltd. is the strategic consultant for its business growth and marketing. The company is on a mission to ensure 'Reachability, Affordability & Quality' of the products, across the globe for a healthier and happier world.

Wasazra has a portfolio into tablets, injections, syrups, capsules, soft-gelatin capsules and sachets. The product line falls into anti-allergic, anti-bacterial injections, calcium and multivitamin tablets and pre-biotic.

The company further intends to expand its portfolio by adding anti-cancer, anti-malarial, vaccines and anti-emetic drugs. Wasazra aims to set up a state of the art self-manufacturing facility which will generate employment and contribute towards Pradhan Mantri Bharatiya Jan Aushdhi Yojana as public social responsibility.

Fauzan Akhtar, Director Wasazra Pharmaceuticals Ltd. said, "We believe in ethical business model which creates a win-win situation for everyone in the ecosystem. Since 2017, with a small team of MRs and ASMs we have covered major markets in Uttar Pradesh. We plan to become a recognized brand in pharma industry. Wasazra being an Indian company and promoted

under Make in India, we have a huge scope to build business and be in every household as and when required. Speedy introduction of generic drugs into the market is our mainfocus."